Loder 總體耐受性良好 • 第 2 期 PoC c 臨牀試驗研究人員報告説，Loder 治療耐受性良好；安全事件主要與手術有關 — 腫瘤內通過內窺鏡檢查 (EUS) 給予延釋siRNA • N o 治療導致研究中止或死亡的緊急不良事件 (TEAE)，報告了與洛德治療相關的任何生命體徵參數或體格檢查結果研究報告 • 獨立藥物安全監督委員會（DSMB）的審查沒有安全問題或安全限制 • 在子集分析中，未檢測到可測量數量的 Loder（
SIL-204 KRAS G12D/V 和 KRAS 擴增 siRNA 配方
利用 Loder 臨牀數據進一步提高 SIL-204 潛在療效和安全性*EUS 內窺鏡檢查是一項標準程序，用於每 3 個月進行一次超聲引導活檢。SIL-204 LODER `KRAS G12D/V+ KRAS 放大 KRAS G12D/V siRNA 靶標添加疏水鉛以增加 siRNA 進入細胞內和細胞內部的途徑沒有疏水性導線進入腫瘤細胞的作用部位> 48 小時
SIL-204 抑制小鼠體內人類胰腺癌異種移植的生長 • p

SIL-204 在人體血清中體外穩定超過 48 小時 siRNA 鏈置於人體血清中並經過穩定性測試人體血清中 siRNA 鏈的穩定性 siRNA 的潛在效果更長 siRNA 在整個纖維腫瘤環境中的擴散能力更強其他適應症的潛力 0% 20% 30% 50% 60% 70% 90% 100% 0 1 2 4 6 14 24 48% 完整的 SIRNA GUIDE CHRAND LODER SIL-204 18 先前的研究表明 sig12D (Loder) 半衰期在人體血清中為 500萬.n。

SIL-204 在大鼠體內穩定五小時 19 1.吉夫拉里（givorisan）。埃瑪。2.Alnylam。Givosiran NDA 多學科審查。3.盧馬西蘭。評論 (fda.gov)。4.盧馬西蘭。印第安納州萊克維奧——inclisiran (europa.eu)。5.Inclisiran。印第安納州萊克維奧——inclisiran (europa.eu)。6.Inclisiran EMA 評估報告。7.Vutrisiran。美國食品和藥物管理局審查摘要。8.EMA/FDA 批准的 siRNA 藥物：ADME 研究概述和數據解釋。siRNA 的有效性更長 siRNA 在整個纖維腫瘤環境中的擴散能力更強其他適應症的潛力 0 1 2 3 4 5 6 7 8 9 10 SIL-204 Givosiran Lumasiran Inclisiran Inclisiran Vutrisiran Hour SIRNA SIRNA 半衰期 SIRNA 在大鼠和人體血漿中的半衰期（不是頭對頭比較）大鼠的半衰期——人類的壽命可能比大鼠1-8歲高4至6倍 SIL-204 可能是最穩定的 siRNA

SIL-204 LAPC 2023 H1 2024 H1 2025 H 2 2025 H2 2025 H1 2026 LAPC Loder 在 FDA 各方面優化 siRNA 的可批准終點中進行臨牀概念驗證；選擇 SIL-204 採用新的延期發佈配方收到德國聯邦藥品和醫療器械研究所 (bFarm) 的試驗設計指導啟動毒理學研究 SIL-204 啟動 GMP 生產最終配方 SIL-204 在歐盟提交針對局部晚期胰腺患者的 SIL-204 第 2/3 期啟動 SIL-204 的 CTA歐盟20中的癌症表示活動已完成。未標記的待執行活動。

LAPC的SIL-204的第二/三階段試驗：擬議的研究設計得到了德國監管機構對建議的試驗設計的積極指導。第 1 組：SIL-2040+ SOC Chemo Arm 2：SOC Chemo 研究結束第 1 天，2:1 隨機化 dsMB ~ 15 名受試者出於安全考慮，1 個月後FU 如果胰腺切除術後 FU 治療化療運行-中期分析 ~1/3 個事件 P2→P3 Go/No-Go-Go 篩查 28 天每位患者治療期 24 個月或直到死亡或腫瘤太小無法治療長期延期試驗 5 年隨機化療運行——第 2 階段安全運行——第 2 階段擴展第 3 階段 21

世界——著名專家科學顧問委員會艾琳·奧賴利醫學博士紀念館紐約州斯隆·凱特琳温思羅普·洛克菲勒基金會腫瘤內科主席；大衞·魯賓斯坦胰腺癌研究中心醫療計劃聯合主任；德國慕尼黑工業大學Hepatopancreatobi醫學博士Hana Algul，腫瘤代謝系主任；綜合癌症主任德國慕尼黑中心 Klinikum rechts der Isar，Mildred-Scheel-教授，德克薩斯大學醫學博士、安德森癌症醫學博士德克薩斯州休斯敦中心癌症醫學部胃腸道（GI）腫瘤內科教授 Philip A. Philip，醫學博士，密歇根州底特律亨利福特健康中心胃腸道腫瘤學主任；胰腺癌中心聯席主任；亨利福特癌症研究所研究和臨牀護理整合醫學主任 Talia Golan，醫學博士 Sheba Tel Hashomer 醫院，以色列謝巴胰腺癌中心主任-SPCC Katz，MD 德克薩斯大學兼醫學博士安德森癌症中心德克薩斯州休斯敦分校腫瘤外科系主任外科和教授。安德魯·洛伊，醫學博士，加州大學聖地亞哥分校外科腫瘤科主任；外科教授 Mark A. Schattner，醫學博士，紐約州斯隆·凱特琳紀念醫學博士，紐約州胃腸病學、肝病學和營養服務主任 22

經驗豐富的領導團隊伊蘭·哈達爾，工商管理碩士主席兼首席執行官 > 在製藥和高科技公司擁有25年的跨國管理和企業經驗 Mitchell Shirvan，博士，工商管理碩士首席科學與開發官 > 在生物技術公司擁有25年的研發、創新和發現經驗，註冊會計師首席財務官米里特·霍倫什泰因·哈達爾 > 在製藥和高科技領域的上市公司和私營公司高級財務職位有15年的企業融資經驗-科技行業伊蘭·萊文，董事辣木收購公司前董事長兼首席執行官，在以色列高科技相關企業中擁有25年的高管和風險投資/私募股權投資經驗 23

投資亮點 CTA=臨牀試驗申請；IND=研究性新藥。• 臨牀階段，擁有專有癌基因 siRNA 平臺的公司 • 胰腺癌腫瘤內 siRNA 的遞送與系統性 KRAS 抑制劑相比，可獲得更好的藥物暴露 • 在LAPC進行Loder的2期臨牀試驗顯示，FDA批准的總存活終點改善了9.3個月 • 主要候選藥物SIL-204，siRNA穩定性增強，延期效果更好-發佈簡介腫瘤學中的高級 RNA 候選療法後期準備就緒資產具有潛在的監管前進路徑與穩固的知識產權組合建立了牢固的合作伙伴關係 • 德國聯邦藥品和醫療器械研究所（bFarm）關於2/3期試驗的指導意見 • 計劃於2025年底在歐盟提交CTA，並於2026年啟動SIL-204的2/3期試驗 • 建立siRNA和微粒的GMP生產合作夥伴關係 • siRNA和微粒的強大知識產權組合，獨家經營至2043年12月並延期

KRAS Oncogene is a Validated Target for Numerous Cancers 5 Prevalence of The Most Common Types of KRAS Mutations Across Cancers CRC=colorectal cancer; LAPC=locally advanced pancreatic cancer; NSCLC=non - small cell lung cancer. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91. PDAC CRC Non - sq NSCLC Small Bowel Adenocarcinoma Appendix KRAS is the most common oncogenic gene driver in human cancers with gastrointestinal cancers having high percentages of KRAS G12D/V mutations % KRAS mutations 92% 49% 35% 53% 61 %

Pancreatic Cancer Has One of the Highest Mortality Rates of All Major Cancers BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. 1. Bray F, et al. CA Cancer J Clin . 2024;74(3):229 - 263. 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Facts. https:// pancreatic.org /pancreatic - cancer/pancreatic - cancer - facts. 3. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https:// seer.cancer.gov / statfacts /html/ pancreas.html . 4. Gemenetzis G, et al. Ann Surg . 2019;270(2):340 - 347. 5. Kleeff J, et al. Nat Rev Dis Primers . 2016;2:16022. Local Metastatic At diagnosis: 10 - 20% resectable 30 - 40% LAPC + BRPC 50 - 60 % metastatic or systemic Types and Prevalence of Pancreatic Cancer 4,5 6 There are no effective treatment options for our intended indication LAPC 3 rd leading cause today in the U.S. 2 2 nd leading cause by 2030 2 12.8% 5 - year relative survival (2014 - 2020) is one of the poorest in the U.S. 3 Median overall survival for non - resectable PC populations is 14 - 17 months 4

Treating KRAS the Cancer - Driver at the Source and Site of Action Silexion siRNA technology prevents mutated KRAS from being produced while small molecule inhibitors target the functioning KRAS protein Silencing oncogene at the production stage is potentially more efficient and safe approach to treat cancer and overcome treatment - resistance Mutated KRAS gene Mutated KRAS mRNA Functional mutated KRAS protein Transcription Translation Silexion siRNA KRAS small molecule inhibitors ( Systemic delivery) Intratumor delivery Cell proliferation Migration Transformation Survival 7

Intratumor siRNA Administration is Advantageous to Systemic Delivery in Solid Tumors Especially Pancreatic x May overcome the limitations of systemic delivery, and allow obtaining higher intratumor concentrations, and better exposure throughout the primary tumor x Can potentially lead to lower systemic exposure due to limited escape from tumor after intratumor administration x EUS endoscopy provides access to different tumor locations within the affected organ EUS = endoscopic ultrasound; LAPC = locally advanced pancreatic cancer. Solid tumors, such as LAPC, are characterized by excessive fibrous tissue and low blood supply which limit the ability of systemically - administered drug to: 1) Reach to the tumor and within the tumor microenvironment 2) Obtain a sufficient concentration in the tumor for optimum activity Systemic exposure may lead to increased adverse events Limitations of Systemic Delivery Advantages of Intratumor Delivery

G12D G12V G12C G12A G12R Multiple Other KRAS Demographics KRAS mutations are present in ~92% pancreatic cancer cases 1 LAPC = localized advanced pancreatic cancer; ROW=rest of the world.*Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancreatic cancer patients, 70 - 75% with KRAS G12D and G12V mutations and 30 - 35% of cases being LAPC. 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6( 1):91. 2. Yousef, A. et al. NPJ Precis Oncol . 20024;8(1):27. 3. Global Cancer Observatory. Pancreatic Cancer. 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/13 - pancreas - fact - sheet.pdf. 4. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. 2023. https:// seer.cancer.gov / statfacts /html/ pancreas.html . SIL - 204 covers > 74% of KRAS mutations in PDAC 2 KRAS G12C treatment are treating ~1.5% E.U. U.S. 146,477 3 66,400 4 Annual PC cases ~35,000 ~16,000 KRAS - G12D/V mutated LAPC incidence* 9

LODER Phase 2 Trial Data

Phase 2 Trial of Loder Completed in 2023 – a Proof - of - Concept Two - part, open label, study of LODER + SoC chemotherapy vs SoC chemotherapy alone across the U.S. and Israel in patients with non - resectable pancreatic cancer SoC=standard of care. Arm 1: LODER + SOC Chemo (n=18) Day 0 Randomization Long - term follow up Screening Death Determination of eligibility First LODER administration ~7 days later 1 st chemo Week 8 – 1 st CT Arm 2: SOC Chemo (n=11) Every 12 weeks – LODER administration Every 12 weeks – CT Screening Death Determination of eligibility First LODER administration ~7 days later 1 st chemo Week 8 – 1 st CT Arm 2: LODER + SOC Chemo (n=20) Every 12 weeks – LODER administration Every 12 weeks – CT Long - term follow up Cohort 1 (randomized) Cohort 2 (single arm) 11 Key inclusion criteria Non - resectable without signs of metastasis Both cohorts all patients meeting inclusion/exclusion criteria randomized without checking for KRAS mutation status Endpoints Overall survival (OS) Response rate (RR, RECIST v1.1) Safety Tolerability

Baseline Characteristics and Cohorts Information Due to results of a clinical trial indicating FOLFIRINOX’s advantage over GnP as SoC chemotherapy, cohort 2’s SoC chemotherapy was changed from GnP (used in cohort 1) to FOLFIRINOX. *KRAS mutations were determined in 31 patients in total. In cohort 1 , 12 patients in the treatment arm and 10 patients in the control arm were tested; in cohort 1 , 9 patients were tested. BRPC=borderline resectable pancreatic cancer; GnP =gemcitabine/nab - paclitaxel; LAPC=locally advanced pancreatic cancer; SoC=standard - of - care. Cohort 2 (n=20) Cohort 1 (n=29) Single arm Randomized, controlled (SoC) Design/Arms Non - resectable (BRPC+ LAPC) Locally advanced PC (LAPC) Population 62% U .S. ( 4 sites) , 38% Israel (5 sites) Nationality 42% male; 58% female Male/ Female % 64.9 69.7 Median age (years) G12D/V*: Loder 7/9 G12R*: Loder: 2/9 G12D/V*: Loder 11/12, Control 5/10 G12R*: Loder: 1/12, Control 5/10 KRAS Mutations 2.1 2.8 Avg Loder cycles 370 Total number of Loder injections (modified) FOLFIRINOX ((m)FFX) gemcitabine/nab - paclitaxel ( GnP ) SoC chemotherapy 12

Cohort 1 Patients Treated with Loder Bearing KRAS G12D/V Mutation Had 9.3 Months Improvement in Overall Survival 13 * SoC (Control) OS consistent with recent trials for LAPC ( Gemenetzis G, et al. Ann Surg. 2019;270(2):340 - 347). • A subgroup of subjects with the D or V KRAS mutation, the median OS was 691 days for 11 Loder - treated subjects compared to 409 days for 5 SoC subjects • Not powered for statistical significance • Although the primary endpoints of all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting an overall survival advantage of 9.3 months Days OS in Cohort 1 SOC chemo median = 13.4 mo .* siRNA+SOC chemo median= 22.7 mo .

Loder Was Overall Well Tolerated • The Phase 2 PoC c linical trial investigators reported that Loder treatment was well tolerated; Safety events were primarily related to procedure – Intratumor administration of extended - release siRNA via endoscopy (EUS) • N o Treatment Emergent Adverse Events (TEAEs) leading to study discontinuation nor deaths related to Loder treatment reported • No meaningful observations in any vital sign parameter nor any physical examination findings in the study reported • Independent Drug Safety Monitoring Board (DSMB) Reviews had no safety concerns nor safety restrictions • In a subset analysis, no measurable amount of Loder was detected (

SIL - 204 KRAS G12D/V and KRAS amplification siRNA formulation

Leveraging Loder Clinical Data to Further Improve SIL - 204 Potential Efficacy and Safety *EUS endoscopy is a standard procedure used to obtain ultrasound guided biopsies once every 3 months . SIL - 204 LODER ` KRAS G12D/V+ KRAS amplify KRAS G12D/V siRNA target Added hydrophobic lead to increase siRNA access to - and within - the cell No hydrophobic lead Access to tumor cell site of action > 48 hrs

SIL - 204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice • p

SIL - 204 is Stable In Vitro for Over 48 Hours in Human Serum siRNA strand placed in human serum and tested for stability Stability of siRNA Strand in Human Serum Potential longer effectiveness of siRNA Greater ability to diffuse throughout the fibrous tumor environment Potential in other indications 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 1 2 4 6 14 24 48 % OF INTACT SIRNA GUIDE STRAND HOURS LODER SIL-204 18 Previous studies have shown siG12D (Loder) half - life to be 5 min in human serum.

SIL - 204 is Stable In Vivo in Rats for Five Hours 19 1. Givlaari ( givorisan ). EMA. 2. Alnylam. Givosiran NDA MULTI - DISCIPLINE REVIEW. 3. Lumasiran . Review ( fda.gov ). 4. Lumasiran . Leqvio , INN - inclisiran ( europa.eu ) . 5. Inclisiran . Leqvio , INN - inclisiran ( europa.eu ). 6. Inclisiran EMA Assessment Report. 7. Vutrisiran . FDA Review Summary. 8. EMA/FDA Approved siRNA Drugs: ADME Study Overview and Data Interpretation. Longer effectiveness of siRNA Greater ability to diffuse throughout the fibrous tumor environment Potential in other indications 0 1 2 3 4 5 6 7 8 9 10 SIL-204 Givosiran Lumasiran Inclisiran Vutrisiran Hour SIRNA siRNA Half - Life in Rats and Human Plasma (not a head - to - head comparison) Rat Human siRNA half - life in humans is 4 - 6x higher than in rats 1 - 8 potentially suggesting SIL - 204 may be the most stable siRNA

SIL - 204 Development Strategy in LAPC 2023 H1 2024 H 1 2025 H 2 2025 H1 2026 Clinical proof of concept for Loder in LAPC in an approvable endpoint for FDA Optimization of siRNA on various fronts; selection of SIL - 204 with new extended - release formulation Received guidance on trial design from the German Federal Institute for Drugs and Medical Devices ( BfArM ) Initiate toxicology studies SIL - 204 Initiate GMP production final formulation SIL - 204 Submit CTA in E.U. for Phase 2/3 Initiate Phase 2 / 3 of SIL - 204 in patients with locally advance pancreatic cancer in E.U. 20 Indicates completed activity. Unmarked activities to be performed.

Phase 2 / 3 Trial of SIL - 204 in LAPC: Proposed Study Design Received positive guidance from German regulatory agency on suggested trial design. Arm 1: SIL - 204B + SOC Chemo Arm 2 : SOC Chemo End of Study Day 1 , 2:1 Randomization DSMB ~ 15 subjects for safety following 1 mo. FU If pancreatectomy Post Surgery FU Treatment Chemo run - in Interim Analysis ~1/3 events P2→P3 Go/No - Go Screening 28d Death Each Patient Treatment Period 24 months or until death or the tumor is too small to treat Long Term Extension Trial for overall survival 5 yrs from randomization Chemo run - in Phase 2 Safety run - in Phase 2 expanded Phase 3 21

World - Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co - Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul , MD Technical University of Munich, Germany chair for tumor metabolism; Director of the Comprehensive Cancer Center Munich, Germany at the Klinikum rechts der Isar, and Mildred - Scheel - professor and Milind Javle , MD The University of Texas & MD Anderson Cancer Center, Houston, TX Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine Philip A. Philip, MD Henry Ford Health, Detroit, MI Director, Gastrointestinal Oncology; Co - Director, Pancreatic Cancer Center; Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute Talia Golan, MD Sheba Tel Hashomer Hospital,, Israel Head, Sheba Pancreatic Cancer Center - SPCC Matthew Katz, MD The University of Texas & MD Anderson Cancer Center, Houston, TX Department Chair, Department of Surgical Oncology, Division of Surgery and Professor. Andrew M. Lowy, MD UC San Diego, San Diego, CA Chief, Division of Surgical Oncology; Professor of Surgery Mark A. Schattner , MD Memorial Sloan Kettering, NY, NY Chief, Gastroenterology, Hepatology and Nutrition Service 22

Highly Experienced Leadership Team Ilan Hadar , MBA Chairman and Chief Executive Officer > 25 years of multinational managerial and corporate experience with pharmaceutical and high - tech companies Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer > 25 years of experience in R&D, innovation and discovery in biotech companies Mirit Horenshtein Hadar, CPA Chief Financial Officer > 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high - tech industries Ilan Levin, Director Former Chairman & Chief Executive Officer of Moringa Acquisition Corp with 25 years of experience as an executive and venture capital/private equity investor in high - tech, Israel - related ventures 23

Investment Highlights CTA=clinical trial application; IND=investigational new drug. • Clinical - stage company with proprietary oncogene siRNA platform • Intratumor siRNA delivery for pancreatic cancer allow for better drug exposure compared with systemic KRAS inhibitors • Phase 2 clinical trial with Loder in LAPC showed 9.3 months improvement in the FDA approvable endpoint of overall survival • Lead Candidate SIL - 204 with enhanced siRNA stability, and a better extended - release profile Advanced RNA therapeutic candidate in oncology Late - Stage Ready Asset with Potential Regulatory Path Forward Strong Partnerships with Solid IP Portfolio • Guidance received from German Federal Institute for Drugs and Medical Devices ( BfArM ) on Phase 2 / 3 trial • Plans to submit CTA in E.U. late 2025 and initiate Phase 2 / 3 trial of SIL - 204 in 2026 • Established partnerships for GMP production of siRNA and delivery system • Strong IP portfolio for siRNA and microparticles with exclusivity through December 2043 with extension